NeoTherapeutics begins pivotal trial

NEOT began a 500-patient, placebo-controlled U.S. pivotal study of its Neotrofin leteprinim, a small molecule stimulator of neurotrophic factors to treat Alzheimer's disease (AD). NEOT said results fr...